{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICA4LeLjcALDA","lastupdate":"2025-01-21T00:00:00.000Z","update_date":"2025-01-21T00:00:00.000Z","lastModified":"Jan 21, 2025","active":1,"confidence_score":99,"confidence_score_reason":"markets","urlname":"psyrx","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$kTpFhvySWfMfVN0cr0bltQNPUtbnF1e0azyuyRnCm8299oSNDncEuB","name":"PsyRx","oneliner":"Drug Development Using Biological Bioreactor Technology","registrar":"516095668","website":"https://www.psyrx.co/","careerspage":"","founded_month":10,"founded_year":2019,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"https://www.facebook.com/psyrxpsychedelics","linkedin":"https://www.linkedin.com/company/79826212","instagram":""},"social":["https://www.linkedin.com/company/79826212","https://www.facebook.com/psyrxpsychedelics"],"flattenedsociallinks":"https://www.linkedin.com/company/79826212|https://www.facebook.com/psyrxpsychedelics","apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":1,"employees":"1-10","employees_exact":5,"patent":1,"raised":2380000,"stage":"Seed","public_stage":"Seed","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["Psy-Rx","Psy.Rx","Psy Rx"],"about":"PsyRx is a pharmaceutical R&D company developing biological API psilocybin and ibogaine in accordance with GMP standards. Using biological bioreactor technology, the company is focused on becoming a leading producer of GMP-standard ibogaine and psilocybin for use by target customers in the development and production of psychedelic- and ibogaine-based pharmaceuticals, food supplements, and other products.\r\n\r\nPsyRx also aims to develop a revolutionary antidepressant drug based on a combination of ibogaine and existing approved antidepressants, with a focus on reducing side effects and improving efficacy. The companys vision is to develop new drugs for the treatment of depression and addiction by using existing regulatory-approved antidepressant drug formulations with ibogaine. \r\n\r\nIbogaine is also known to affect the brain much like antidepressants, but through different pathways. Therefore, PsyRx believes that there might be synergy between these two drugs, enabling them to treat depression with better efficacy and fewer side effects than existing antidepressants.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+972522988480","country":null,"address":{"israeli":[{"id":"af173413-15ed-4dbb-80b3-dc19170bbaed","city":"Tel Aviv-Yafo","type":null,"address":"Tel Aviv, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"IRdb5jhwj4fEd1DR5gX1u7kV3HdySUL28xFdAb1q2g1CoRsFwE5CD6","date":"Oct 3, 2023","link":"https://www.haaretz.com/haaretz-labels/medica/2023-10-04/ty-article-labels/.premium/psyrxs-innovative-next-generation-plant-based-solution-for-depression/0000018a-f9d0-df89-a7bb-fdf9af300000","source":"www.haaretz.com","visible":1,"analysis":{"tags":"Pharmaceuticals, Mental Health","company":"PsyRx","layoffs":"Not mentioned","summary":"PsyRx, a Rehovot-based company, is developing natural pharmaceutical-grade psychedelics for mental health therapeutics. The company is working on a medication that combines ibogaine, a substance derived from the Tabernanthe Iboga plant, with an approved SSRI anti-depressant. The company believes this combination will be more effective and have fewer side effects than existing antidepressants. PsyRx is also investigating the therapeutic potential of psilocybin, sourced from hallucinogenic mushrooms. The company is currently conducting a Series C financing round through the online equity-based crowd-investing platform ExitValley, with TrippyVC being a major investor.","partners":["Hebrew University’s Robert H. Smith Faculty of Agriculture, Food & Environment","University of Athens"],"customers":"Not mentioned","investors":["TrippyVC"],"confidence":8,"key_topics":["Depression Treatment","Psychedelics","Clinical Trials","Investment","Partnerships"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"Growth-Positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"Growth-Positive","analysisId":"P5eqIouCV3ruzJp5DOu7yHuyWuMInb2OTz8Rb9QWPsKqU8mCiBeBPb","news_summary":"PSYRX'S INNOVATIVE NEXT-GENERATION- PLANT-BASED SOLUTION FOR DEPRESSION","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"267966a3-5965-4179-b70f-e4b70571119e","date":"Feb 22, 2022","link":"https://www.prnewswire.com/news-releases/psyrx-announces-appointment-of-prof--itamar-grotto-as-new-executive-chairman-of-the-board-301487341.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"Management Changes, Drug Discovery","company":"PsyRx Ltd","layoffs":"N/A","summary":"PsyRx Ltd, a pharmaceutical company specializing in drug discovery for mental health conditions, has appointed Professor Itamar Grotto as its Executive Chairman. This follows the recent renewal of the companys license to conduct R&D in Psilocybin and Ibogaine by the Israeli Ministry of Health. Prof. Grotto, a Public Health Physician and Professor of Epidemiology, has previously served as the Director of Public Health Services and the Associate Director General at the Israeli Ministry of Health. He was also a member of the Executive Board of the World Health Organization.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Management Appointment","Drug Discovery","Mental Health","Psilocybin","Ibogaine"],"date_of_event":"Feb. 22, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"G0WwdNp2UBsni8Jygijjg8CYFNdxoHWNC5XaDj6knstW75rQs5dNjH","news_summary":"PsyRx Announces Appointment of Prof. Itamar Grotto as New Executive Chairman of the Board","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ba1d3ece-d6ad-4977-bafa-e3e80f079813","date":"Feb 9, 2022","link":"https://www.jpost.com/health-and-wellness/mind-and-spirit/article-695925","source":"www.jpost.com","visible":1,"analysis":{"tags":"Management Changes","company":"PsyRx","layoffs":"N/A","summary":"PsyRx, an Israel-based pharmaceutical company, has announced the appointment of Prof. Itamar Grotto as the new Executive Chairman of their scientific advisory board. Prof. Grotto was the former Associate Director-General of the Health Ministry between 2017 and 2021, a Public Health Physician and Professor of Epidemiology, and a WHO Executive Board Member. The company focuses on treating mental health conditions by producing and researching GMP-grade Psilocybin and Ibogaine for drug purposes.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["New Appointment","Pharmaceutical Research"],"date_of_event":"February 9, 2022","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Management Changes"],"acquisition_amount":"N/A","structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Oaf7fJsLMa35HF28Omg7hPtjMOtOoBv8QmwPZOvEGXFoJhElUuyHlI","news_summary":"https://www.jpost.com/health-and-wellness/mind-and-spirit/article-695925","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"67c93f8c-3d92-4d2e-8158-680b999be3e7","date":"Jan 3, 2022","link":"https://www.israel21c.org/now-psychedelics-are-coming-to-your-medicine-cabinet/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"Pharmaceuticals, Psychedelics","company":"PsyRx","layoffs":"Not mentioned","summary":"PsyRx, an Israeli company, is developing standardized pharma-grade psychedelics from natural sources to treat mental health issues. The company uses an agro-medical bioreactor to produce psychedelic botanic extracts psilocybin and ibogaine, which have shown positive effects in treating depression, anxiety, addiction, and other conditions. PsyRx is focusing on the potential of ibogaine to improve current SSRI antidepressants. The company is planning to start small animal trials soon to check safety and efficacy, with hopes to start human trials in a year. PsyRx has raised a couple of million dollars from private investors and plans to go public.","partners":"Not mentioned","customers":"Not mentioned","investors":"Private investors","confidence":9,"key_topics":"Psychedelics, Mental Health, Drug Development, Investment, Expansion","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"A couple of million dollars","structured_issues":"Investment, Expand","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment, Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"bNXA0U7z50VnywwNwc9uWw3zrll408tgi3tiLHJVvwFagm4Ls9ux4T","news_summary":"Now psychedelics are coming to your medicine cabinet","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"bb50d94e-75ad-4165-8d1f-34f05a61267d","date":"Sep 3, 2021","link":"https://www.maariv.co.il/business/tech/Article-863002","source":"www.maariv.co.il","visible":1,"analysis":{"tags":"Pharmaceuticals, Depression Treatment","company":"PsyRx","layoffs":"Not mentioned","summary":"Israeli company PsyRx is developing innovative drugs for the treatment of depression and addiction. The companys vision is to develop a new drug composed of a combination of an existing drug with extracts from mushrooms and the root of the iboga plant. The company is working on the development of intellectual property of growth and extraction methods of the iboga root and psilocybin, for use as raw materials in drugs through bio-reactors. The company initially will only produce the raw materials for other companies that will register the products as drugs. The process is in its most advanced stages and has even received significant financial investment.","partners":"Hebrew University in Jerusalem","customers":"Not mentioned","investors":"Not mentioned","confidence":8,"key_topics":"Depression Treatment, Psychedelic Drugs, Pharmaceuticals, Research, Investment","date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not specified","structured_issues":"Investment","acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"qBOT5euUHwQaO5TXcj8m0LGgmsGjiyi7vy8eCCZghqv0Ys2jeZJj4O","news_summary":"חברה ישראלית מפתחת תרופות חדשות לטיפול בדיכאון עם מרכיב מפתיע","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"198f902c-36c9-4c66-9cee-e776372dfa6d","date":"Jul 12, 2021","link":"https://www.jpost.com/health-science/israeli-lab-grows-magic-mushrooms-to-treat-depression-673524","source":"www.jpost.com","visible":1,"analysis":{"tags":"Pharmaceutical Research","company":"PsyRx","layoffs":"Not mentioned","summary":"Israeli pharmaceutical R&D company, PsyRx, is developing psilocybin and other biological psychoactive compounds using biological bioreactor technology. The companys main focus is on depression and addiction treatment. It also manufactures high-standard ibogaine, a psychoactive alkaloid effective in reducing addiction severity. The companys bioreactor allows it to grow more sterile and consistent compounds than would be possible in nature. PsyRx has completed its initial goals of growing psilocybin on solid and liquid surfaces and has begun its prior-to-submission phase to the FDA for approval to test an Ibogaine-based micro-dosed antidepressant drug.","partners":"Not mentioned","customers":"Not mentioned","investors":"Not mentioned","confidence":9,"key_topics":["Psilocybin","Depression Treatment","Addiction Treatment","Bioreactor Technology","Ibogaine"],"date_of_event":"July 12, 2021","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"sy6srksAlM4PnqIP6ktCqw4oVmBKw6hpIZqG5pbLOAYivxNCWPfR5A","news_summary":"https://www.jpost.com/health-science/israeli-lab-grows-magic-mushrooms-to-treat-depression-673524","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[{"id":"XuUwjYzY0ixwVLjhGA0VKtCvUBOuLjhn6XrNSy8qzQwjlOvmAJY45z","timestamp":"2023-11-29 18:11:42.000000","resources_type":2,"resources_title":"","resources_file_name":"YllemkpJmT8","alt":"","imageurl":"https://img.youtube.com/vi/YllemkpJmT8/0.jpg","url":"http://youtu.be/YllemkpJmT8"}],"tags":["mental-health","pharma-companies","treatments","pharmaceuticals","food-industry","drug-development"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Nvx3J0KDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2019-10-01","name":"Method for In-vitro manufacturing secondary metabolites in inboga root suspension and psilocybin suspension bioreactor","tags":null,"category":"Agriculture, Food & Nutrition","tto_logo":"/image_cloud/yissum_tto_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6","university_logo":"/image_cloud/yissum_institution_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":[],"geomarkets":[],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":0,"lastfunding":"$330K","totalrounds":3,"fundingstage":"Seed","totalfunding":"$2.38M","publicinvestors":0,"lastpublicfunding":330000,"totalpublicrounds":3,"totalpublicfunding":2380000},"team":[{"name":"Asher  Holzer","email":"asher@psyrx.co","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4K-o47kLDA","bounced":false,"claimed":0,"founder":1,"urlname":"asher-holzer","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgt6u6ywoM","position":"Co-founder & Chairman","last_name":"Holzer","claimtoken":"U4XCNUijTYP8FWyZwkCBoy9m8WWYhsejgrvkDHUiKQtnYgacJaAhdG","first_name":"Asher ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/asher-holzer-2302361a5/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-11-29 18:04:34.000000","initials":"AH","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Yoav  Elishoov","email":"yoav@psyrx.co","phone":"","gender":"Male","userid":"EjatOerqet84ScDXbDoVFHhgLuqKm8B8nB3ZsKn9dCs8kduSu4vAdT","bounced":false,"claimed":null,"founder":0,"urlname":"yoav-elishoov","visible":1,"memberid":"eNlptV5oX3IKicix6q0noyoIR0m9P0aQWr5lLyfr8Dg5CtJr7WPkEK","position":"CEO","last_name":" Elishoov","claimtoken":"sHoFblDpxkReSYAssmbe8sPPj7em8g2kGpmqT6Sn6tyMdlbSQIjU6f","first_name":"Yoav","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/yoav-elishoov-1984711/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":"2023-11-29 18:06:29.000000","initials":"Y ","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Itay Hecht","email":"itay@psyrx.co","phone":"0522988480","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4Pea9pcKDA","bounced":false,"claimed":1,"founder":1,"urlname":"itay-hecht-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgz9XfkwkM","position":"Co-founder & BizDev","last_name":"Hecht","claimtoken":"41db514271eae4b264e42241ae5792078215754d68f9a209bb451d848f302ea7","first_name":"Itay","picturekey":"$vEAKSiossqFKDbxwCoB9zPmFKjTjO0UZwWBlMHXlBgmsavk9bOBafG","claimeddate":"2021-07-29","linkedinurl":"https://www.linkedin.com/in/itay-hecht-1698ba126/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2021-07-29 10:57:15.000000","initials":"","pictureurl":"https://storage.googleapis.com/clean-finder-353810/$vEAKSiossqFKDbxwCoB9zPmFKjTjO0UZwWBlMHXlBgmsavk9bOBafG","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Kobi  Buxdorf","email":"kobi@psyrx.co","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4M-26I8KDA","bounced":false,"claimed":0,"founder":1,"urlname":"kobi-buxdorf-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgj-zfxgkM","position":"Co-founder & CTO","last_name":"Buxdorf","claimtoken":"XgeBNsLewLn8o6hQ8DuoPxPImYVhpD2mTJTPlUUdWOb2Ft11AYxmF7","first_name":"Kobi ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/kobi-buxdorf-ph-d-mba-1bb05a35/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-11-29 18:04:31.000000","initials":"KB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Noam  Barnea-Ygael","email":"noam@psyrx.co","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4M_bqugJDA","bounced":false,"claimed":0,"founder":0,"urlname":"noam-barnea-ygael","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDg7_aw5goM","position":"Research Officer","last_name":"Barnea-Ygael","claimtoken":"nhLHsfgbAu2L1XSUQD0yhhNT4wcbjAStJ7BugjrWbn2L9IXcCvOYIz","first_name":"Noam ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/noam-barnea-ygael-2520446a/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2023-11-29 18:06:24.000000","initials":"NB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoNqyo8cLDA","fullname":"Yotam Maman"},"biverifydate":"2021-07-04T00:00:00.000Z","crunchbaseid":"","lastupdator":"Matan Eblagon","lastupdator_email":"matane@sncentral.org","creator":"Yanina Wainscheinker","creator_email":"yanina.wain@gmail.com","createdate":"2021-07-01T00:00:00.000Z","biverification":"Yotam Maman","sectorverification":null,"affiliatedOrganizations":null,"timeline":[{"id":"DS7MDoFaEc4P6bVatFzmKsuiArKh2D64sEJZ8oQM1w7WZXp3k2NOGU","date":"Jul 2023","amount":"$330K","source":"the founder","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":330000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"MPSfsZ9c9Oq1c2Ft0x6eM6vd3unw0QLT5eyidWV19XUkLkR9d5DAiV","date":"Aug 2022","amount":"$550K","source":"the founder","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":550000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"66jhkiYiRTBUY5e9zbNIFZQqCTChFZZdff7spjaNulr0YYiiVorhWY","date":"Dec 2020","amount":"$1.5M","source":"the founder","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"10/2019","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"PsyRx","logourl":"https://storage.googleapis.com/clean-finder-353810/$kTpFhvySWfMfVN0cr0bltQNPUtbnF1e0azyuyRnCm8299oSNDncEuB","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$kTpFhvySWfMfVN0cr0bltQNPUtbnF1e0azyuyRnCm8299oSNDncEuB","seoabout":"PsyRx is a pharmaceutical R&D company developing biological API psilocybin and ibogaine in accordance with GMP standards. Using biological bioreactor techn...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":5,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Herbals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA>Herbals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|2:>TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA/Herbals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Life Sciences","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals","children":[{"title":"Herbals","key":"0-0-0","path":"TechnologyClassificationModel>Biologicals>Herbals"}]}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":2,"name":"Herbals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4IeQlIIIDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals","Herbals"],"targetCustomer":["Healthcare & Life Sciences","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"inline","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"DS7MDoFaEc4P6bVatFzmKsuiArKh2D64sEJZ8oQM1w7WZXp3k2NOGU","date":"Jul 2023","amount":"$330K","source":"the founder","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":330000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"MPSfsZ9c9Oq1c2Ft0x6eM6vd3unw0QLT5eyidWV19XUkLkR9d5DAiV","date":"Aug 2022","amount":"$550K","source":"the founder","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":550000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"66jhkiYiRTBUY5e9zbNIFZQqCTChFZZdff7spjaNulr0YYiiVorhWY","date":"Dec 2020","amount":"$1.5M","source":"the founder","eventtype":"FundingRoundEvent","investment":[],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Pre-Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":1500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}